Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2000 1
2002 1
2005 1
2006 1
2008 2
2009 3
2010 2
2011 6
2012 5
2013 4
2014 6
2015 6
2016 3
2017 3
2018 1
2019 2
2020 5
2021 7
2022 3
Text availability
Article attribute
Article type
Publication date

Search Results

55 results
Results by year
Filters applied: . Clear all
Page 1
PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer.
van den Heerik ASVM, Horeweg N, Nout RA, Lutgens LCHW, van der Steen-Banasik EM, Westerveld GH, van den Berg HA, Slot A, Koppe FLA, Kommoss S, Mens JWM, Nowee ME, Bijmolt S, Cibula D, Stam TC, Jurgenliemk-Schulz IM, Snyers A, Hamann M, Zwanenburg AG, Coen VLMA, Vandecasteele K, Gillham C, Chargari C, Verhoeven-Adema KW, Putter H, van den Hout WB, Wortman BG, Nijman HW, Bosse T, Creutzberg CL. van den Heerik ASVM, et al. Among authors: mens jwm. Int J Gynecol Cancer. 2020 Dec;30(12):2002-2007. doi: 10.1136/ijgc-2020-001929. Epub 2020 Oct 12. Int J Gynecol Cancer. 2020. PMID: 33046573 Free PMC article.
Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy.
Wortman BG, Creutzberg CL, Putter H, Jürgenliemk-Schulz IM, Jobsen JJ, Lutgens LCHW, van der Steen-Banasik EM, Mens JWM, Slot A, Kroese MCS, van Triest B, Nijman HW, Stelloo E, Bosse T, de Boer SM, van Putten WLJ, Smit VTHBM, Nout RA; PORTEC Study Group. Wortman BG, et al. Among authors: mens jwm. Br J Cancer. 2018 Oct;119(9):1067-1074. doi: 10.1038/s41416-018-0310-8. Epub 2018 Oct 25. Br J Cancer. 2018. PMID: 30356126 Free PMC article. Clinical Trial.
Fifteen-year radiotherapy outcomes of the randomized PORTEC-1 trial for endometrial carcinoma.
Creutzberg CL, Nout RA, Lybeert ML, Wárlám-Rodenhuis CC, Jobsen JJ, Mens JW, Lutgens LC, Pras E, van de Poll-Franse LV, van Putten WL; PORTEC Study Group. Creutzberg CL, et al. Among authors: mens jw. Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e631-8. doi: 10.1016/j.ijrobp.2011.04.013. Epub 2011 Jun 2. Int J Radiat Oncol Biol Phys. 2011. PMID: 21640520 Free article. Clinical Trial.
Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial.
Nout RA, Smit VT, Putter H, Jürgenliemk-Schulz IM, Jobsen JJ, Lutgens LC, van der Steen-Banasik EM, Mens JW, Slot A, Kroese MC, van Bunningen BN, Ansink AC, van Putten WL, Creutzberg CL; PORTEC Study Group. Nout RA, et al. Among authors: mens jw. Lancet. 2010 Mar 6;375(9717):816-23. doi: 10.1016/S0140-6736(09)62163-2. Lancet. 2010. PMID: 20206777 Clinical Trial.
Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer--A pooled analysis of PORTEC 1 and 2 trials.
Bosse T, Peters EE, Creutzberg CL, Jürgenliemk-Schulz IM, Jobsen JJ, Mens JW, Lutgens LC, van der Steen-Banasik EM, Smit VT, Nout RA. Bosse T, et al. Among authors: mens jw. Eur J Cancer. 2015 Sep;51(13):1742-50. doi: 10.1016/j.ejca.2015.05.015. Epub 2015 Jun 3. Eur J Cancer. 2015. PMID: 26049688 Clinical Trial.
Defining Substantial Lymphovascular Space Invasion in Endometrial Cancer.
Peters EEM, León-Castillo A, Smit VTHBM, Boennelycke M, Hogdall E, Hogdall C, Creutzberg C, Jürgenliemk-Schulz IM, Jobsen JJ, Mens JWM, Lutgens LCHW, van der Steen-Banasik EM, Ortoft G, Bosse T, Nout R. Peters EEM, et al. Among authors: mens jwm. Int J Gynecol Pathol. 2022 May 1;41(3):220-226. doi: 10.1097/PGP.0000000000000806. Epub 2021 Jul 13. Int J Gynecol Pathol. 2022. PMID: 34261899
Patients' and clinicians' preferences in adjuvant treatment for high-risk endometrial cancer: Implications for shared decision making.
Post CCB, Mens JWM, Haverkort MAD, Koppe F, Jürgenliemk-Schulz IM, Snyers A, Roeloffzen EMA, Schaake EE, Slot A, Stam TC, Beukema JC, van den Berg HA, Lutgens LCHW, Nijman HW, de Kroon CD, Kroep JR, Stiggelbout AM, Creutzberg CL. Post CCB, et al. Among authors: mens jwm. Gynecol Oncol. 2021 Jun;161(3):727-733. doi: 10.1016/j.ygyno.2021.03.004. Epub 2021 Mar 10. Gynecol Oncol. 2021. PMID: 33712276 Free article.
Brachytherapy quality assurance in the PORTEC-4a trial for molecular-integrated risk profile guided adjuvant treatment of endometrial cancer.
Wortman BG, Astreinidou E, Laman MS, van der Steen-Banasik EM, Lutgens LCHW, Westerveld H, Koppe F, Slot A, van den Berg HA, Nowee ME, Bijmolt S, Stam TC, Zwanenburg AG, Mens JWM, Jürgenliemk-Schulz IM, Snyers A, Gillham CM, Weidner N, Kommoss S, Vandecasteele K, Tomancova V, Creutzberg CL, Nout RA; PORTEC Study Group. Wortman BG, et al. Among authors: mens jwm. Radiother Oncol. 2021 Feb;155:160-166. doi: 10.1016/j.radonc.2020.10.038. Epub 2020 Nov 5. Radiother Oncol. 2021. PMID: 33159971 Free article.
55 results